Latest news with #SteveScala
Globe and Mail
01-08-2025
- Business
- Globe and Mail
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and AbbVie (ABBV)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY – Research Report) and AbbVie (ABBV – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Eli Lilly & Co (LLY) TD Cowen analyst Steve Scala maintained a Buy rating on Eli Lilly & Co today and set a price target of $960.00. The company's shares closed last Thursday at $763.28. According to Scala is a 4-star analyst with an average return of 6.7% and a 60.4% success rate. Scala covers the Healthcare sector, focusing on stocks such as Elanco Animal Health, GlaxoSmithKline, and Merck & Company. ;'> The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1028.80 average price target, which is a 37.7% upside from current levels. In a report issued on July 17, TR | OpenAI – 4o also upgraded the stock to Buy with a $885.00 price target. AbbVie (ABBV) In a report released today, Matt Phipps from William Blair maintained a Buy rating on AbbVie. The company's shares closed last Thursday at $194.50. According to Phipps has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.6% and a 41.1% success rate. Phipps covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Janux Therapeutics Inc, and Vertex Pharmaceuticals. ;'> Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $212.46, which is a 7.8% upside from current levels. In a report issued on July 16, TR | OpenAI – 4o also upgraded the stock to Buy with a $206.00 price target.
Business Insider
09-07-2025
- Business
- Business Insider
Merck & Company (MRK) Gets a Hold from Bernstein
In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Merck & Company. The company's shares closed yesterday at $81.37. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Moderna. According to TipRanks, Breen has an average return of 3.3% and a 61.90% success rate on recommended stocks. In addition to Bernstein, Merck & Company also received a Hold from TD Cowen's Steve Scala in a report issued on June 26. However, on July 7, J.P. Morgan maintained a Buy rating on Merck & Company (NYSE: MRK). Based on Merck & Company's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $15.53 billion and a net profit of $5.08 billion. In comparison, last year the company earned a revenue of $15.78 billion and had a net profit of $4.76 billion Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRK in relation to earlier this year. Most recently, in April 2025, Dalton Smart, the SVP Fin. – Global Controller of MRK sold 4,262.00 shares for a total of $352,723.12.
Business Insider
27-06-2025
- Business
- Business Insider
TD Cowen Sticks to Their Hold Rating for Merck & Company (MRK)
TD Cowen analyst Steve Scala maintained a Hold rating on Merck & Company (MRK – Research Report) yesterday. The company's shares closed yesterday at $78.83. Confident Investing Starts Here: According to TipRanks, Scala is a 4-star analyst with an average return of 6.2% and a 56.45% success rate. Scala covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Sanofi, and Elanco Animal Health. In addition to TD Cowen, Merck & Company also received a Hold from Citi's Geoff Meacham in a report issued on June 24. However, on June 18, Goldman Sachs maintained a Sell rating on Merck & Company (NYSE: MRK). The company has a one-year high of $132.29 and a one-year low of $73.31. Currently, Merck & Company has an average volume of 15.89M. Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRK in relation to earlier this year. Most recently, in April 2025, Dalton Smart, the SVP Fin. – Global Controller of MRK sold 4,262.00 shares for a total of $352,723.12.
Globe and Mail
15-04-2025
- Business
- Globe and Mail
TD Cowen Remains a Hold on Pfizer (PFE)
TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company's shares closed yesterday at $22.12. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Scala covers the Healthcare sector, focusing on stocks such as Merck & Company, Pfizer, and AstraZeneca. According to TipRanks, Scala has an average return of 4.2% and a 55.62% success rate on recommended stocks. In addition to TD Cowen, Pfizer also received a Hold from Citi's Geoff Meacham in a report issued today. However, yesterday, Jefferies maintained a Buy rating on Pfizer (NYSE: PFE). Based on Pfizer's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $17.76 billion and a net profit of $410 million. In comparison, last year the company earned a revenue of $14.25 billion and had a GAAP net loss of $3.34 billion Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is neutral on the stock. Last month, JENNIFER B. DAMICO, the SVP & Controller of PFE sold 3,249.00 shares for a total of $84,373.90.
